Skip to Content
  • Previous Rank
    17
  • Revenue 3 Yr Annual Growth Rate
    32%
  • Revenue 3 Yr Growth Rank
    48
  • EPS 3 Yr Annual Growth Rate
    58%
  • EPS 3 Yr Growth Rank
    30
  • Total Return 3 Yr Annual Rate
    -4%
  • Total Return 3 Yr Rank
    96

Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.

Company Information

Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Location
Foster City, Calif.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak3
Years on List8
CEO
John Milligan
Websitehttp://www.gilead.com

Revenue, Net Income

Revenue past four quarters ($M)$29,101
Net Income past four quarters ($M)$12,637

Growth Rates and Ranks

Revenue 3 Yr Growth Rank48
Revenue 3 Yr Annual Growth Rate32%
EPS 3 Yr Growth Rank30
EPS 3 Yr Annual Growth Rate58%
Total Return 3 Yr Rank96
Total Return 3 Yr Annual Rate-4%
Beat S&P 500 (9.6%)
no
P/E Ratio9